3.49 USD
▲+0.05+1.75%
盘后 3.47 +1.17%
2026-08-03
市值
$269.79M
市盈率
—
EPS
-0.86
股息率
—
52 周区间
1.35 – 4.60
成交量
805.24K
Beta
0.96
目标价
9.00
52W 低 1.3552W 高 4.60
价格走势
公司简介
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran...